To reduce risk of additional problems, take Vitamin D if you have a Vitamin D problem (Psoraisis in this case)
Associations of serum 25-hydroxyvitamin D concentrations with risks of mortality and cardiovascular disease among individuals with psoriasis
American Academy of Dermatology, Volume 93, Issue 3 10.1016/j.jaad.2025.05.1380 Behind paywall
Kaiqing Lin, PhDa,b,c ∙ Ya Miao, MDa,b,c ∙ Lu Gan, MDa,b,c ∙ … ∙ Ru Wang, PhDe [email protected] ∙ Xiang Chen, MD, PhDc,f,g,h [email protected] ∙ Jiaqi Huang, PhDa,b,c [email protected] …
Background
Evidence remains scarce regarding the relationship between serum 25-hydroxyvitamin D (25(OH)D) and the risk of mortality and cardiovascular disease (CVD) in psoriasis.
Objective
To explore the potential protective effect of serum 25(OH)D on the risk of mortality and CVD among patients with psoriasis.
Methods
This cohort study included 8947 psoriasis patients and 178,937 controls identified at baseline in the UK Biobank cohort. Serum 25(OH)D levels were prospectively collected at the time of recruitment. Multivariable-adjusted Cox proportional hazards regression models were used to evaluate the associations between levels of serum 25(OH)D and risk of overall mortality and CVD incidence.
Results
Compared to the lowest level of serum 25(OH)D (<25 nmol/L), hazard ratios were 0.54 and 0.78 for overall mortality and incident CVD for the highest level of serum 25(OH)D (≥50 nmol/L) among psoriasis patients, respectively (all P < .05). Psoriasis patients with serum 25(OH)D ≥ 50 nmol/L appeared to have no excess risk of mortality and CVD incidence, compared with matched controls.
Limitations
Information on psoriasis subtypes was not available.
Conclusion
A higher level of serum 25(OH)D was associated with a reduced risk of overall mortality and CVD in individuals with psoriasis.